Researchers from the Berlin-based partner institutions of eight German Centers for Health Research (DZG) will gather on November 11, 2026, for the very first DZG Berlin Day at Charité – Universitätsmedizin Berlin, Campus Virchow-Klinikum. The event will focus on new therapies, the translation of research findings into clinical practice, and cross-disease collaboration among the centers.
How can new research insights reach patients more quickly? And what opportunities arise from collaboration that transcends both disease-specific and institutional boundaries? These are the central questions of the inaugural DZG Berlin Day, where approximately 200 guests from science, medicine, politics, and patient advocacy groups are expected to attend at the Charité Campus Virchow-Klinikum.
The eight German Centers for Health Research (DZG) pool the expertise of universities, university hospitals, and non-university research institutions from across Germany. Together, they aim to rapidly translate medical research on diseases of high societal importance into practical applications for prevention, diagnostics, and therapy, thereby achieving a sustainable improvement in public health.
Berlin provides an ideal setting for this event: Five of the German Centers for Health Research (DZG) are represented in the capital through own partner institutions: German Cancer Consortium (DKTK), German Center for Cardiovascular Research (DZHK), German Center for Child and Adolescent Health (DZKJ), German Center for Neurodegenerative Diseases (DZNE) and German Center for Mental Health (DZPG). Additionally, Berlin-based associated partners include the German Center for Infection Research (DZIF), the German Center for Lung Research (DZL) and the German Center for Diabetes Research (DZD).
A key focus of the day, moderated by science and education journalist Dr. Jan-Martin Wiarda, is translation – the pathway from scientific discoveries to clinical application. Following the opening remarks by Prof. Dr. Ulrich Kintscher, Vice Dean for Research at Charité – Universitätsmedizin Berlin, and welcoming messages from Ministerial Director Thomas Romes of the Federal Ministry of Research, Technology and Space, as well as Dr. Henry Marx of the Berlin Senate Department for Higher Education and Research, Health and Long-Term Care, the eight DZG centers will present their respective missions.
PD Dr. Lena Oevermann, from the Department of Pediatrics specializing in Oncology and Hematology at Charité and the DZKJ, will subsequently demonstrate how translation is achieved in practice, using the example for a novel CRISPR therapy. In the following panel discussion, “New Therapies – Opportunities of Translational Research in the DZG”, representatives from research, clinical practice, spin-offs, and industry will discuss the opportunities and challenges on the path toward new therapies.
Furthermore, more established and early-career researchers from the DZGs will present their research findings through short presentations and a poster session.
Many challenges in health research span multiple disease areas simultaneously. The close-knit networking within the DZG provides the foundation to strategically leverage synergies and drive new momentum in prevention, diagnostics, and therapy. Consequently, the afternoon will focus on further collaboration between the centers. Following an introduction by Prof. Dr. Isabel Dziobek from German Center for Mental Health, participants will engage in four interactive, cross-center sessions focusing on topics of relevance to multiple disease areas and researchers across all DZG centers: prevention, patient engagement, Artificial intelligence as a bridge to new therapies, and collaboration with Network of University Medicine (NUM).
The inaugural DZG Berlin Day is intended to create a lasting impact far beyond the event itself. The objective is to more effectively integrate existing expertise within the Berlin research landscape, spark new collaborations, and identify shared research priorities.
The DZG Berlin Day is a joint event of the German Centers for Health Research. The DZG are funded by the Federal Ministry of Research, Technology and Space, as well as by the respective federal states in which they are based.
How do scientific discoveries lead to new therapies, diagnostics, and health innovations? The German Centers for Health Research (DZG) will address this question at BIO-Europe in Cologne from November 9–11, 2026. At booth 7-42, the eight centers will showcase innovative technologies, translational research projects, and successful spin-offs, demonstrating how cutting-edge research can reach patients faster.
The DZG are also using this international partnering platform to present promising technologies and research approaches to potential development, industry, and investment partners. The goal is to initiate new collaborations that accelerate the translation of scientific findings into tangible solutions for patients.
Representatives from all eight DZG centers will be available for discussions at the joint booth. Fact sheets will showcase current technologies, innovations, and projects from their respective portfolios. In addition, experts from the technology transfer offices will offer individual consultations and 1:1 partnering meetings focused on DZG technologies, patents, and collaboration opportunities.
A special highlight of the program is the fireside chat session “Cracking the Translation Gap: Lessons from Germany’s Coordinated Translational Research Model”. DZG spokesperson Prof. Stefanie Dimmeler and Prof. Heiko Lickert, a researcher at the German Center for Diabetes Research (DZD) and founder of Viacure GmbH, will discuss how research networks, effective technology transfer, and entrepreneurial engagement can help turn scientific breakthroughs into innovative health solutions.
The DZG look forward to connecting with researchers, companies, investors, and other stakeholders who are actively shaping the future of medicine.
https://informaconnect.com/bioeurope/
Researchers at the German Center for Lung Research (DZL), based at the Airway Research Center North (ARCN), have identified a previously overlooked cellular pattern in the tumor microenvironment that provides important insights into the long-term survival prospects of patients with non-small cell lung cancer (NSCLC). The findings have been published in the European Journal of Cancer.
Until now, research has primarily focused on immune cells that directly infiltrate tumors. However, the team led by DZL researcher PD Dr. Sebastian Marwitz at the Research Center Borstel, Leibniz Lung Center, has shown that immune cells unable to enter the tumor and instead remaining in the surrounding connective tissue (stroma) also provide valuable information about disease progression.
For the study, the researchers analyzed tissue samples from 674 patients with NSCLC from Germany and Sweden. Using multiplex immunofluorescence, they identified, classified, and mapped the spatial distribution of more than six million immune cells within the tissue.
Their analyses revealed five distinct immune cell composition patterns and three different spatial organization patterns within the stroma. The results demonstrate that not only the abundance of specific immune cell types but also their spatial organization plays a crucial role. The architecture of immune cells remaining in the stroma proved to be an independent predictor of long-term survival—a relationship that has not previously been described.
Patients with a high density of B cells in the stroma and a close spatial association between helper T cells and regulatory T cells showed particularly favorable long-term survival. Importantly, this prognostic signature could be reduced to just three established immune markers, potentially paving the way for a comparatively simple prognostic test. "These findings highlight that diseases behave in a much more complex way than previously assumed. It is not only the abundance of individual cell types that matters, but also how they are spatially organized and interact with neighboring cells. This research approach is a central component of our work at the Research Center Borstel and the German Center for Lung Research," said PD Dr. Sebastian Marwitz.
Future studies will investigate whether the identified immune signature also predicts outcomes in patients with advanced or metastatic lung cancer and in those receiving immunotherapy.
The study was conducted within the framework of the Airway Research Center North (ARCN) of the DZL in collaboration with Uppsala University and LungenClinic Grosshansdorf. "The successful realization of this project was only possible thanks to the close collaboration and combined expertise of our international consortium. Scientific advances like these are the result of strong collaborative research," emphasized DZL researcher Prof. Dr. Torsten Goldmann, Head of Histology at the Research Center Borstel, Leibniz Lung Center.
Original publication: Marwitz S, Brunnström H, Gulyas M, et al. Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival. European Journal of Cancer 2026 Jun 9:244:116868. DOI: 10.1016/j.ejca.2026.116868
SOURCE: DZL
A spatial analysis of proteins in human blood vessels shows why some deposits tear more easily. A team from the DZHK site in Munich reports on this in Nature Cardiovascular Research.
Deposits in the carotid artery, known as plaques, are among the most common causes of stroke. The most dangerous plaques are not necessarily the largest ones that narrow the vessels, but rather those that tear easily. They can trigger a stroke even when the vessel narrowing was not previously particularly noticeable. For those affected, such an event often comes completely unexpectedly.
A research team involving the German Centre for Cardiovascular Research (DZHK), the Technical University of Munich (TUM) and the TUM University Hospital has now investigated, for the first time, the spatial distribution of proteins in different regions of such plaques. The results show why some plaques become unstable and are more prone to rupture. At the same time, the researchers identified PCSK9, a well-known regulator of lipid metabolism, as a possible local marker for particularly dangerous plaques.
Whether a plaque becomes dangerous depends largely on its fibrous cap. This separates the fat-rich core of the plaque from the bloodstream. If this protective layer tears, a blood clot can form within a short time, triggering a stroke. Why the cap becomes unstable in some plaques is, as yet, only partially understood.
For the study, the researchers analysed tissue samples from 112 patients who had undergone surgery due to severe narrowing of the carotid artery. Using a high-resolution method, they examined the necrotic tissue core, the fibrous cap and the vessel wall of each plaque separately. In total, they identified almost 4,900 different proteins and were able to show where these occur within the plaque.
It emerged that unstable plaques differ from more stable ones mainly in the area of the necrotic tissue core and the fibrous cap. There, the researchers found increased evidence of inflammation, changes in lipid metabolism, remodelling of the supporting tissue, and calcification processes. The vessel wall itself showed considerably fewer differences.
"We have known for a long time that it is not the size of a plaque alone that is decisive, but its stability. With our spatial analysis, we can for the first time precisely trace which molecular processes take place in the various regions of a plaque. This opens up new possibilities for better identifying dangerous plaques and treating them more specifically in the long term," says one of the study's two senior authors, Prof. Lars Maegdefessel of TUM University Hospital Munich/DZHK site Munich.
The protein PCSK9, already known from lipid metabolism, was particularly conspicuous. It occurred locally more frequently in unstable plaques than in more stable ones. In further experiments, the researchers were able to show that vascular smooth muscle cells produce and release more PCSK9 under inflammatory and oxidative stress. This indicates that PCSK9 not only influences cholesterol metabolism but may also be directly involved in the changes that make plaques unstable.
Original publication: Sinha A, Sachs N, Kratz E, et al. Proteomics reveals spatial and molecular heterogeneities in advanced atherosclerotic carotid artery plaques. Nat Cardiovasc Res. Published online June 22, 2026. doi:10.1038/s44161-026-00827-1
SOURCE: DZHK
Diagnosing Autism Spectrum Disorder (ASD) in Germany currently takes, on average, until a child reaches seven years of age. This is far too late, as earlier support significantly improves developmental outcomes. Researchers at the German Center for Mental Health (DZPG) are working to fundamentally improve this process through digital technologies.
Prof. Dr. Christine Falter-Wagner, Heisenberg Professor of Clinical Developmental Psychology at LMU University Hospital Munich and a researcher at DZPG, is pursuing an innovative approach. Rather than relying solely on time consuming interviews and subjective behavioral observations, her team uses advanced sensor technology to capture communication behavior and analyzes the resulting data using machine learning methods.
Specifically, multiple channels of communication are recorded simultaneously, including eye movements, facial expressions, body movements, speech patterns, and physiological signals.
A particular focus of the research is interpersonal synchrony, which refers to the degree to which two people are attuned to one another during a conversation. Neurotypical individuals generally demonstrate more finely coordinated interaction patterns than people on the autism spectrum, for example in the alignment of gaze and gestures.
These differences can be detected by AI algorithms with an accuracy of 80 to 90 percent based on just ten minute video recordings.
Another important advantage of the method is its ability to distinguish autism from other mental health conditions with similar symptoms, such as borderline personality disorder, social anxiety disorder, or attention deficit/hyperactivity disorder (ADHD). This type of differentiation remains a major challenge in current diagnostic practice and frequently contributes to misdiagnosis.
Falter-Wagner emphasizes that technology is not intended to replace clinical assessment: “Technology assisted diagnostics cannot replace clinical diagnostics, as the latter also includes developmental history, among other factors. Ultimately, a comprehensive clinical evaluation remains decisive for diagnosis. Nevertheless, technologies can support clinicians in the future and help reduce waiting times for diagnostic assessments.”
The next phase of the project involves a large scale validation study across multiple clinics, funded by the Innovation Fund of the Federal Joint Committee (G-BA).
In addition, a companion study will investigate how individuals with autism and their family members perceive and accept this new form of digital diagnostics.
Original Publication: Koehler JC, Dong MS, Bierlich AM, et al. Machine Learning Classification of Autism Spectrum Disorder Based on Reciprocity in Naturalistic Social Interactions. Translational Psychiatry. 2024;14(1):76. Published February 3, 2024. doi: 10.1038/s41398-024-02802-5.
SOURCE: DZPG
Magdeburg (Germany), June 10, 2026. People with “mild cognitive impairment” (MCI) are at higher risk of developing dementia. Indeed, many of them experience a gradual decrease in cognitive performance over time. Smartphone- or tablet-based memory tests can capture this subtle decline more quickly than conventional testing. These findings come from a study by DZNE in collaboration with university hospitals in Germany, the University of Wisconsin–Madison in the United States, and the start-up neotiv. In the researchers’ view, digital tests like these could help accelerate clinical trials for new dementia drugs, particularly regarding Alzheimer’s disease. Over the longer term, they also see potential for use in clinical routine. The results were published in the scientific journal npj Digital Medicine and are based on data from about 200 older adults.
“Conventional methods for assessing cognitive performance are based on standardized tasks that must be completed orally or in writing – and importantly, under supervision,” explains Dr. David Berron, who leads a research group at DZNE’s Magdeburg site. Berron is also a co-founder of the company “neotiv,” whose app was used in the current study. “By contrast, the current study involved self-administered at-home memory tests using the neotiv Trials app, which allow us to collect what are known as digital biomarkers. The results show that this approach can also provide information about how cognitive performance changes over time. This subtle cognitive decline can even be detected within shorter periods of time, as measurements can be performed more frequently than with conventional methodology. While we did use a particular app, in my view these results have broader implications: They provide the first evidence that cognitive decline can be assessed using remote digital tools.”
The current study included a total of 202 women and men from Germany and the United States. Participants ranged in age from 52 to 85 years; 50 of them had MCI. People with this condition are generally still able to manage well in everyday life. However, their cognitive performance is measurably impaired.
Prior studies have already established that this particular mobile app, whose testing principle is based on DZNE research, can identify MCI. The current study now shows that this self-administered testing is also sensitive enough to track subtle changes in cognitive performance over time. “From a medical perspective, what matters is not only whether MCI is present, but also whether the symptoms remain stable or worsen,” Berron explains.
According to Dr. Sarah Polk, first author of the current publication and a colleague of David Berron, the app’s mobile approach has key advantages: “Testing can be done at home, at your own pace. All you need is a smartphone or tablet – there’s no need to visit a study center or make an appointment. This makes it easy to repeat the test at short intervals with little effort.”
In this way, changes in cognitive performance can be tracked more closely than with conventional methods, allowing effects to be detected within a relatively short period of time, Polk explains: “With the conventional approach, the considerable effort involved means that testing is realistically possible only once or twice a year. In contrast, our participants used the app for around seven to twelve months and tested themselves with it about every two weeks. During this period, we were already able to observe a decline in cognitive performance among people with MCI.”
The reliability of such results is not a given – a new method first has to show that it truly measures what it is meant to measure. This requires a suitable benchmark: In the current study, long-term clinical data were available for every participant, gathered over an average of eight years using established procedures. The long-term trajectory derived from these data was consistent with the app-based results obtained over only a few months – providing evidence for the digital measurement’s validity. “What I found particularly impressive was that, with just a few months of app use, we were able to capture a signal that aligns with years of clinical observations. That gives us confidence that this method really measures what it is supposed to measure,” Polk adds.
“Therapy development is an obvious area of application for our digital approach – in other words, evaluating new medications for dementia,” Berron says. In this context, the goal is to determine whether and how well an experimental drug can slow mental decline – ideally already at the stage of MCI, which is considered a potential precursor to dementia. “A digital approach could help speed up clinical trials, because it could make it possible to determine whether the drug being tested has the desired effect more quickly than with conventional methods.” Looking ahead, once a larger body of data is available, this approach could be applied not only in research but also in routine clinical care, Berron surmises. “In my view, there are two practical use cases: firstly, assessing whether cognitive abilities are developing in an age-appropriate way; and secondly, monitoring an ongoing treatment to determine whether it is having the desired effect,and to what extent. Essentially, digital assessment can facilitate individual patient monitoring.”
Alzheimer’s disease, the most common form of dementia, spreads gradually, progressively damaging more and more areas of the brain. The app accounts for this phenomenon: its four subtasks, which involve memorizing images of objects and rooms or identifying differences between images, target different memory functions and therefore different brain regions. Among the participants with MCI, performance on two of these tasks was already severely impaired at the start of the study and no further decline could be measured. “This suggests that the associated brain regions had already been damaged to such an extent that they had reached the lower limit of their functional capacity,” Berron says. In the other two tasks, however, a gradual decline in performance over time could be measured as disease progressed.
App-based tests, or subtasks, that no longer detect changes in individuals with MCI, may nevertheless be important in even earlier disease stages, Berron suspects. “In the earliest disease stage, subtle cognitive impairment may already be present that we simply cannot measure using conventional tests. We now aim to take a closer look at whether the digital approach might help in this regard.”
SOURCE: DZNE
The link between diabetes and cardiovascular disease can be studied even more intensively in the future: The German Research Foundation (DFG) has announced that it will provide funding for the multi-site Collaborative Research Center (CRC) 1774, “CARDIO-DIABETES-CROSSTALK.” Participants in the project include the German Diabetes Center (DDZ) and other researchers from the DZD.
“The CRC opens up new opportunities for us to systematically research the spectrum of cardiometabolic diseases. Our goal is to develop new screening methods for early detection and establish them in everyday clinical practice—not only to improve care for people with diabetes and cardiovascular disease, but also to prevent these conditions from developing in the first place,” emphasizes Professor Michael Roden, Scientific Director and Spokesperson of the Board of the DDZ as well as Director of the Department of Endocrinology and Diabetology at the University Hospital Düsseldorf (UKD) and DZD board member.
Around 9.5 million people in Germany have diabetes, and the prevalence is on the rise. The condition is often accompanied by other comorbidities. For example, the risk of cardiovascular disease is significantly higher in people with type 2 diabetes. The new CRC “CARDIO-DIABETES-CROSSTALK” will investigate exactly how this link arises, focusing on the causes and biological processes underlying both diseases. The goal is to identify the key molecular factors and cellular interactions that can explain how metabolic disorders develop and inflammation arises. To this end, the CRC will focus on investigating both the molecular processes in the affected organs and the effects that a disruption in energy metabolism has on the cardiovascular system.
The CRC will benefit from the excellent infrastructure on the UKD campus at Heinrich Heine University (HHU)—particularly due to its proximity to the CARDDIAB (“translational science building for CARDiovascular research in DIABetes”) research building, which is currently under construction. Here, preclinical and clinical research on diabetes and cardiovascular disease, the development of new strategies for maintaining public health, and the creation of personalized therapies will be brought together.
Prof. Robert Wagner, Head of the Research Group Clinical Research Center at the DDZ and senior physician at the Department of Endocrinology and Diabetology at the UKD, will serve as co-spokesperson: “With funding from the DFG, we can study diabetes and cardiovascular disease in greater detail as a common disease continuum. We aim to closely integrate the precise characterization of people with diabetes and molecular analyses. Our goal is to better understand why certain people with diabetes or prediabetes develop cardiovascular complications at an early stage—and to use this understanding to develop new approaches for early detection and targeted prevention.” Prof. Maria Grandoch, Head of the Institute for Translational Pharmacology at HHU, will assume the role of spokesperson for the CRC.
Other participants at the Düsseldorf site include PD Dr. Oana-Patricia Zaharia (DDZ, Department of Endocrinology and Diabetology at the UKD) and Prof. Eckhart Lammert (DDZ, Institute of Metabolic Physiology at HHU). Researchers from the Institute of Diabetes and Obesity at DZD partner Helmholtz Munich are also involved in the project.
The project proposal submitted to the DFG involved funding totaling more than 11 million euros over a term of almost four years.
SOURCE: DZD
Scientific highlights, transdisciplinary research, and new collaborations will be the focus of DZG Munich Day on July 29, 2026. For the fourth time, the eight German Centers for Health Research (DZG) in Munich are inviting scientists at all career stages to learn about the latest research findings, exchange ideas across centers, and explore joint research strategies and innovative technologies.
Bearing the slogan “Munich meets Munich”, DZG Munich Day is aimed specifically at researchers from Munich who are affiliated with one of the eight German Centers for Health Research. In addition, scientists from DZG sites throughout Germany are participating.
The event has become established as a key platform for scientific exchange in health research. Last year, more than 200 guests from the fields of research, healthcare, politics, and scientific organizations took advantage of the opportunity to network and launch new research projects.
The event will be opened by Prof. Martin Hrabě de Angelis, Scientific Director and Spokesperson for Helmholtz Munich and member of the DZG Executive Board. Moreover, the Federal Minister of Research, Technology, and Space, Dorothee Bär, will deliver a welcome address via video message. Thereafter, Prof. Stefanie Dimmeler, spokesperson for the DZG Executive Board, will provide an update on current developments and joint activities of the German Centers for Health Research.
A particular highlight is the panel discussion on the topic “AI Meets Drug Repurposing.” A panel of high-profile experts—including Kamyar Hadian (Drug Discovery), Ralf Huss (Managing Director, BioM), Giulia Magno (physician-scientist), Julia Schnabel (AI for Biomedical Imaging), Stephan Sieber (chemist), and Fabian Theis (AI expert) will discuss how artificial intelligence (AI) can be used to identify new indications for existing or approved drugs. Michael von Bergwelt (spokesperson for DKTK Munich) will moderate the discussion.
Even though the various widespread diseases differ in their manifestations, they often share common biological causes and mechanisms. The DZG's strong network of institutions opens up unique opportunities to develop innovative research approaches and translate them more quickly into medical application.
Therefore, DZG Munich Day gives particular focus on the cooperation between the centers. Among other things, the presentation will feature current transdisciplinary projects on the following topics:
In addition, participants can look forward to a diverse program covering current topics in research and science management:
The event also offers a wide range of opportunities for networking and establishing new partnerships. Researchers at all career stages—from early-career scientists to principal investigators (PIs)—are given the opportunity to discuss shared perspectives and challenges in translational health research.
4th DZG Munich Day - DZG – Deutsche Zentren der Gesundheitsforschung
For the first time, scientists from five German Centers for Health Research came together at the DZG Lower Saxony Day in Hanover. The event provided cardiologists, infectious disease specialists, lung researchers, and experts in neurodegenerative diseases as well as child and adolescent health with an opportunity for interdisciplinary exchange and regional networking.
More than 100 representatives from politics, research institutions, and funding organizations met at Medical Park Hanover on April 17, 2026, to discuss how medical innovations can be translated more rapidly into patient care. The following DZGs were represented:
In his welcoming remarks, Lower Saxony’s Minister of Science and Culture, Falko Mohrs, emphasized the significance of the DZG for biomedical research in Lower Saxony and underscored how crucial close collaboration between politics and science is for rapidly translating new scientific findings into clinical applications for the benefit of patients.
Dr. Georg Schütte of the VolkswagenStiftung spoke from a personal perspective about the founding of the DZG during his time as State Secretary at the BMBF (now BMFTR), and was also quoted by Stefanie Dimmeler (acting DZG spokesperson), who reminded the audience that the DZG was not intended simply to provide more funding for what had always been done. The central mission of the DZG is translational research. The scientists impressively demonstrated that this is being implemented in the subsequent program.
The event focused on closer scientific collaboration within the DZG. In presentations and poster sessions, the scientists showcased diverse and outstanding translational research projects, local research priorities, and the latest therapeutic and technological developments. The significance of translating research findings into new therapies to improve patients’ health and quality of life was emphatically illustrated through the personal perspectives of two young patient representatives.
In addition, examples of successful spin-offs from the DZG in Lower Saxony were vividly presented, and DZG- and site-internal support options for product development and spin-offs were demonstrated.
Another key objective of the program was networking and exchange at the strategic level. How can we better leverage technologies, service structures, and existing expertise together, create new synergies, and optimally support young talents in biomedical and clinical research?
The 1st DZG Day Lower Saxony was a successful kick-off event to explore these questions and strengthen the research network across all DZGs in Lower Saxony. We look forward to building on the momentum generated and translating it into concrete actions. Further joint events will follow.
8th DZG Dresden Day, 11 May 2026
4th DZG Munich Day, 29 July 2026
2nd DZG Heidelberg-Mannheim Day, 21 September 2026
1st DZG Berlin Day, 11 November 2026
One of the earliest warning signs of cardiovascular disease happens deep within the smallest blood vessels: tiny changes in their ability to expand and contract, known as microvascular endothelial dysfunction (MiVED). Until now, it has been extremely difficult to detect or measure these changes in humans. Researchers from Helmholtz Munich and the Technical University of Munich (TUM), member institutions of the German Centre for Cardiovascular Research (DZHK), have developed a solution: fast-RSOM.
The new technique uses pulses of light that generate ultrasound to create extremely detailed 3D images of the skin and the smallest blood vessels. This makes it possible to detect early changes that remain invisible to conventional methods.
“With fast-RSOM, we can, for the first time, non-invasively assess endothelial dysfunction at single-capillary and skin-layer resolution in humans,” says Dr. Hailong He, first author of the study and researcher at the Institute of Biological and Medical Imaging at Helmholtz Munich and TUM. Dr Angelos Karlas, co-first author, Vascular Surgeon and Senior Research Scientist at TUM University Hospital, adds: “Our novel approach offers an unprecedented view of how cardiovascular disease manifests at the microvascular level.”
Until now, clinicians have lacked a precise and non-invasive way to detect or measure these early changes in humans. Fast-RSOM can support cardiovascular health on several levels. It provides indications of increased risk before symptoms occur, helps tailor lifestyle changes or therapies more precisely, and enables monitoring of whether preventive measures or treatments are effective.
The research team now aims to test fast-RSOM in larger and more diverse patient groups and to integrate the high-resolution MiVED biomarkers provided by fast-RSOM into routine clinical practice. The device is portable, quick to deploy and non-invasive, meaning it could in future be used in hospitals and GP surgeries to regularly assess cardiovascular risk and monitor heart health in patients.
RSOM (Raster Scan Optoacoustic Mesoscopy) is a non-invasive imaging technology that uses pulses of light to generate ultrasound signals, producing highly detailed 3D images of structures beneath the skin. It can detect tiny changes in blood vessels, oxygen levels, and tissue composition that are invisible to traditional imaging. By combining high contrast with depth, RSOM enables early detection of diseases such as cardiovascular problems and diabetes. Its compact design could make advanced diagnostics more accessible outside specialized labs. The technology was developed by the team led by Prof. Vasilis Ntziachristos. He is a Principal Investigator at the German Centre for Cardiovascular Research, Director of the Bioengineering Center at Helmholtz Munich, and Professor of Biological Imaging at the Technical University of Munich.
Source: DZHK
For the first time, an international analysis has shown that when people with prediabetes bring their blood glucose back into the normal range through lifestyle changes, their risk of heart attack, heart failure, and premature death is cut in half. These findings could revolutionize prevention and establish a new, measurable target for clinical guidelines. Among others, researchers from the German Center for Diabetes Research (DZD), University Hospital Tübingen, and Helmholtz Munich took part in the study.
Millions of people in Germany live with elevated blood glucose levels without knowing it. They are considered to have “prediabetes” – an early stage that until now has lacked clearly defined treatment targets. People with prediabetes are usually advised to lose weight, be more physically active, and eat a healthier diet. These lifestyle changes make sense, as they improve fitness, well-being, and several risk factors. However, one crucial question has remained unanswered: Do they also protect the heart in the long term? So far, no lifestyle program for people with prediabetes has been able to clearly demonstrate a sustained reduction in heart attacks, heart failure, or cardiovascular deaths over decades.
A joint analysis of two of the world’s largest diabetes prevention studies, from the United States and China, now provides clarity. Together with colleagues in the U.S. and China, researchers from the DZD, University Hospital Tübingen, and Helmholtz Munich were able to show that the decisive factor is apparently not the lifestyle change itself, but whether people with prediabetes manage to bring their blood glucose back into the normal range – in other words, whether they achieve remission of prediabetes.
Long-term data from more than 2,400 people with prediabetes show that those who succeed in normalizing their blood glucose have a significantly lower risk of dying from cardiovascular disease or being hospitalized for heart failure than those whose glucose levels remain elevated, even when both groups lose a similar amount of weight. In both studies, participants’ risk of cardiovascular death was reduced by roughly 50%, and overall mortality also fell significantly. The U.S. study followed its participants for 20 years, while its Chinese counterpart tracked participants for 30 years.
Under the leadership of the Tübingen team, these datasets were harmonized and reanalyzed to compare rates of cardiovascular death and hospitalization for heart failure in people with and without prediabetes remission.
Cardiovascular prevention has so far rested on three pillars: blood pressure control, lowering LDL cholesterol, and smoking cessation. With these new findings, a fourth pillar could be added: sustained normalization of blood glucose in prediabetes. “Our results suggest that remission of prediabetes not only delays or prevents the onset of type 2 diabetes, as already known, but also protects people from serious cardiovascular diseases in the long term, over the span of decades,” says Professor Dr. Andreas Birkenfeld, a board member of the DZD and Medical Director of Department of Medicine IV at University Hospital Tübingen. A fasting blood glucose value of ≤ 97 mg/dL proved to be a simple marker for a persistently lower risk of heart disease, regardless of age, weight, or ethnic background. This threshold could be applied in primary care practices worldwide, making prevention more tangible.
Germany is lagging behind when it comes to preventive health care. According to the current Public Health Index, the country ranks second to last among 18 European nations in implementing evidence-based prevention measures. As a result, the risk of dying from cardiovascular disease is significantly higher in Germany than in many neighboring European countries.
The new study highlights the untapped potential and shows how concrete target values can improve public health. “We see a clear therapeutic window: If glucose levels are normalized already at the prediabetes stage, the long-term risk of heart attack, heart failure, and premature death can be markedly reduced. Our data support explicitly anchoring remission as a primary treatment goal in guidelines for the prevention of diabetes and cardiovascular disease,” urges Professor Birkenfeld.
SOURCE: DZD
For many people with dementia, remaining at home for as long as possible is a major wish. However, care can be complex: medication is not always taken as prescribed, outpatient care services go unused, or there is insufficient support with household tasks and transportation to medical appointments. This is where the “Dementia Care Management” program developed by the German Center for Neurodegenerative Diseases (DZNE) comes in. Specially trained nursing staff support those affected and their relatives with organization and care and, for the first time, are also permitted to take on medical tasks that would otherwise be reserved for physicians. The Innovation Committee of the Joint Federal Committee (G-BA) recommends integrating Dementia Care Management into routine care.
The benefits of Dementia Care Management (DCM) have been demonstrated by the InDePendent study, which involved more than 400 participants from Mecklenburg–Western Pomerania, Brandenburg, and Hesse.
“The positive vote coming from the G-BA now gives this approach further momentum. We are very committed to implementing dementia care management in practice,” said Prof. Wolfgang Hoffmann, a health services researcher at the DZNE site in Rostock/Greifswald.
In the study, the researchers examined for the first time what it means when dementia care managers, after passing a state examination, are granted medical responsibilities that are otherwise reserved exclusively for physicians. These include, for example, administering injections, prescribing care aids, and treating complex wounds. The dementia care managers carried out these tasks in close consultation with the treating family doctors. “At the same time, the involved family doctors were effectively relieved of part of their workload, as they usually have very limited capacity for home visits,” explains Dr. Anika Rädke, researcher at the DZNE and first author of the scientific publication on the current study.
From the perspective of health insurance companies, Dementia Care Management initially incurs higher costs than standard care—but evaluations show that the concept is cost-effective overall. “You have to consider the savings. Dementia Care Management helps to avoid costs,” says Wolfgang Hoffmann. “If care managers perform medical tasks instead of physicians, it is more economical. In addition, better nursing care contributes to overall health, preventing treatment costs that would otherwise be expected in the long term. Our current findings, together with long-term data from previous projects, show that Dementia Care Management is cost-effective overall.”
Long-term data from previous projects also show that Dementia Care Management helps delay the move to a nursing home—aligning with the wishes of many individuals who want to live independently at home for as long as possible.
The benefits have therefore been scientifically proven, and its integration into standard care is explicitly recommended. The researchers responsible for the Greifswald study now hope that this successful care concept will become a reimbursable service covered by health insurance companies in the future, thereby benefiting many people with dementia in the long term.
Source: DZNE
You are currently viewing a placeholder content from Google Maps. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from OpenStreetMap. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Mapbox. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from hCaptcha to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More Information